January 9, 2020

Ramy Farid, Ph.D.
President and Chief Executive Officer
Schr dinger, Inc.
120 West 45th Street, 17th Floor
New York, New York 10036

       Re: Schr dinger, Inc.
           Amendment No. 1 to Draft Registration Statement on Form S-1
           Filed December 13, 2019
           CIK No. 0001490978

Dear Dr. Farid:

     We have reviewed the supplemental response submitted on January 7, 2020 to
comment letter and have the following comment.

       Please respond to this letter by providing the requested information and
either submitting
an amended draft registration statement or publicly filing your registration
statement on
EDGAR. If you do not believe our comment applies to your facts and
circumstances or do not
believe an amendment is appropriate, please tell us why in your response.

      After reviewing the information you provide in response to the comment
and your
amended draft registration statement or filed registration statement, we may
have additional

Supplemental Response dated January 7, 2019

Prospectus Summary
Our Drug Discovery Business, page 8

1.     We have reviewed the supplemental materials provided in response to the
comment in our
       letter dated December 18, 2019 and have the following comments:

           Please limit your tabular presentation of programs in the summary
and the business
           section to those in which you have a direct financial interest.
Disclose the material
           terms of each collaboration and licensing agreement and file the
agreements as
           exhibits to the registration statement. The material terms should
include quantified
           disclosure of milestone payments made or received to date, the
aggregate amount of
           potential milestone payments and the nature of optional fees. Please
note that listing
 Ramy Farid, Ph.D.
Schr dinger, Inc.
January 9, 2020
Page 2
           aggregate potential revenues assuming all product candidates achieve
all approvals
           and milestones is not appropriate.
           To the extent you have an indirect financial interest in a program
as a result of an
           equity interest in the collaborator, you may identify your equity
interests in these
           entities. Your disclosure should identify the collaborator, your
ownership interest
           and whether you have any control over the collaborator and the
           program. If you do not have any control over the entity or the
program, you may
           disclose any license agreements but should not describe their
product development
           Please delete references to undisclosed programs. If you have a
direct material
           interest in a program, you should identify it.
           Please explain the extent to which you have access to information
related to clinical
           trial results, serious adverse events and ongoing communications
with the FDA
           relating to collaborators' current programs or the extent to which
the collaborator is
           required to provide you with this information.
           With respect to the disclosure on page 107, please expand the
discussion of Morphic
           to describe your interest in Morphic and the clinical trials
supporting the IND,
           including the clinical end points and results.
           Please also disclose the Agios Pharmaceuticals therapies that were
approved by the
           FDA and your financial interest in these therapies.

       You may contact Tracey McKoy at (202) 551-3772 or Brian Cascio at (202)
551-3676 if
you have questions regarding comments on the financial statements and related
matters. Please
contact Chris Edwards at (202) 551-6761 or Celeste Murphy at (202) 551-3257
with any other

FirstName LastNameRamy Farid, Ph.D.
                                                            Division of
Corporation Finance
Comapany NameSchr dinger, Inc.
                                                            Office of Life
January 9, 2020 Page 2
cc:       Scott Lunin
FirstName LastName